fopflash plasmids Search Results


m51 super 8x fopflash plasmids  (Addgene inc)
94
Addgene inc m51 super 8x fopflash plasmids
M51 Super 8x Fopflash Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/pmc06351844__ACEL___18___e12844___s001-1-1-19?v=Addgene+inc
Average 94 stars, based on 1 article reviews
m51 super 8x fopflash plasmids - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
firefly top- or fopflash luciferase plasmids  (Biomol GmbH)
90
Biomol GmbH firefly top- or fopflash luciferase plasmids
Firefly Top Or Fopflash Luciferase Plasmids, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/10__1074_slash_jbc__m801818200-52-22-12?v=Biomol+GmbH
Average 90 stars, based on 1 article reviews
firefly top- or fopflash luciferase plasmids - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
reporter plasmids 33 mutated tcf-binding site (fopflash)  (Promega)
90
Promega reporter plasmids 33 mutated tcf-binding site (fopflash)
Reporter Plasmids 33 Mutated Tcf Binding Site (Fopflash), supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/10__1128_slash_mcb__21__17__5857___5868__2001-99-1-16?v=Promega
Average 90 stars, based on 1 article reviews
reporter plasmids 33 mutated tcf-binding site (fopflash) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
fopflash plasmid  (Merck KGaA)
90
Merck KGaA fopflash plasmid
(A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by <t>FOPflash-normalized</t> <t>TOPflash</t> luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.
Fopflash Plasmid, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/pmc05522218-143-17-23?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
fopflash plasmid - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
plasmid carrying a minimal c-fos promoter driving luciferase expression (fopflash)  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare plasmid carrying a minimal c-fos promoter driving luciferase expression (fopflash)
(A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by <t>FOPflash-normalized</t> <t>TOPflash</t> luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.
Plasmid Carrying A Minimal C Fos Promoter Driving Luciferase Expression (Fopflash), supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/10__1074_slash_jbc__m502168200-49-21-56?v=Johns+Hopkins+HealthCare
Average 90 stars, based on 1 article reviews
plasmid carrying a minimal c-fos promoter driving luciferase expression (fopflash) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
fopflash reporter plasmids  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare fopflash reporter plasmids
(A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by <t>FOPflash-normalized</t> <t>TOPflash</t> luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.
Fopflash Reporter Plasmids, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/10__1074_slash_mcp__m900139___mcp200-71-2-16?v=Johns+Hopkins+HealthCare
Average 90 stars, based on 1 article reviews
fopflash reporter plasmids - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
transfection plasmids topflash and fopflash  (Promega)
90
Promega transfection plasmids topflash and fopflash
(A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by <t>FOPflash-normalized</t> <t>TOPflash</t> luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.
Transfection Plasmids Topflash And Fopflash, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/pmc07339185-126-18-24?v=Promega
Average 90 stars, based on 1 article reviews
transfection plasmids topflash and fopflash - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
topflash/fopflash plasmids  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare topflash/fopflash plasmids
(A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by <t>FOPflash-normalized</t> <t>TOPflash</t> luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.
Topflash/Fopflash Plasmids, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/pm27604867-92-0-13?v=Johns+Hopkins+HealthCare
Average 90 stars, based on 1 article reviews
topflash/fopflash plasmids - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
reporter plasmids fopflash  (Merck KGaA)
90
Merck KGaA reporter plasmids fopflash
(A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by <t>FOPflash-normalized</t> <t>TOPflash</t> luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.
Reporter Plasmids Fopflash, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fopflash+plasmids/10__1002_slash_ctd2__113-32-41-48?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
reporter plasmids fopflash - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


(A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by FOPflash-normalized TOPflash luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.

Journal: Oncotarget

Article Title: Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells

doi: 10.18632/oncotarget.17056

Figure Lengend Snippet: (A) Cell viability of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 24 or 48 h. Data are presented as mean±SD. Experiments were performed in triplicate. (B) Relative TCF/LEF luciferase activity measured by FOPflash-normalized TOPflash luciferase activityin RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. (C) RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 1 h. The mRNA expression of indicated genes was detected by qRT-PCR analysis. (D and E) The expression of TCF4-interacting proteins and phosphorylation of TNIK detected by immunoprecipitation and Western blot of RPMI8226 cells treated with IL-6 (50 ng/mL) and KY-05009 (3 μM) or dovitinib (3 μM) alone or in combination for 9 h. * P < 0.01, * P < 0.001 versus control; # P < 0.01, ## P <0.001 versus cells treated with IL-6 alone.

Article Snippet: RPMI8226 cells were trasfected with TOPflash TCF reporter plasmid (wild-type TCF binding site) (Merck Millipore, Darmstadt, Germany), FOPflash plasmid (mutant TCF binding site) (Merck Millipore, Darmstadt, Germany), and Lipofectamine 2000 (Thermo Fisher Scientific, Boston, MA, USA) in an antibiotic-free medium.

Techniques: Luciferase, Activity Assay, Expressing, Quantitative RT-PCR, Phospho-proteomics, Immunoprecipitation, Western Blot, Control